A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
about
Chapter 7: PharmacogenomicsGenetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarctionMassively parallel sequencing: the next big thing in genetic medicineA C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding riskClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenetics and anaesthesia: the value of genetic profilingInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinThe c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patientsWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsA genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin doseTherapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north IndiansWarfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.Estimation of the warfarin dose with clinical and pharmacogenetic data.Literature mining on pharmacokinetics numerical data: a feasibility study10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Integration of genetic, clinical, and INR data to refine warfarin dosing.Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides.Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin.Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed modelScreening for 392 polymorphisms in 141 pharmacogenes.Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert systemEvaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum.Implementing genotype-guided antithrombotic therapy.A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.An integrative method for scoring candidate genes from association studies: application to warfarin dosing.Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.Pharmacogenetics of anticoagulants.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Understanding and preventing drug-drug and drug-gene interactions.Common VKORC1 and GGCX polymorphisms associated with warfarin dose.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.The future prospects of pharmacogenetics in oral anticoagulation therapy.Novel associations of VKORC1 variants with higher acenocoumarol requirements.CYP4F2 genetic variant alters required warfarin dose
P2860
Q21563496-44BE8B7F-819D-44EC-8BC3-A588A75B3A12Q24311573-0E30114E-4117-47F8-B1F2-FE15751BF4C7Q24653648-2DA3EED6-7339-4A2B-9CD4-0F7260E5240EQ24817078-ED46AA60-B76A-4F51-99FA-1AD81D438156Q26823542-F43696BF-B72B-43B8-B6CE-C0CC68F11E93Q26859221-7ADECDC2-8630-4DA5-A2F7-9C556DF2F647Q27002899-9422F76D-853D-40C7-90FE-E6A1A9CE9649Q28276514-CF40FC53-8998-49F9-A7D8-FBEA3EB6CA90Q28306899-63B7E42A-13EA-49CB-91A7-F6B53B35A0FEQ28395337-58472322-FD77-4288-9BAF-04BD0E51AA0AQ28475004-B0D1FD5A-D9DA-4D66-9D86-7F42AE490689Q28483861-240051B7-315F-4BCF-9580-445B4F4186B8Q31131437-655B6DEC-A80C-4A86-8283-706BD99BA86EQ33311569-3E3B188C-C2A6-4736-B547-FD3B8EC8C1B0Q33410725-A9CDC205-5366-4D6D-83C3-78F83B93BF61Q33426634-C0B84686-1461-4961-B083-B6A21A6AA548Q33517162-404AEF1D-DCCD-4484-A07F-B8C2B04BDF5EQ33550741-C792C5A0-F8C1-402A-8EFC-AE8AC95F3731Q33575234-16876647-405E-4895-833E-F0A943002AFAQ33591624-245A6EA0-AEAE-42B2-B88F-D77C8093FAFAQ33593601-7A5E0AE5-60F5-415F-A5E0-B13C2C58AC6EQ33733501-1AF042A8-5A5A-4054-92BB-284F4AD4E26EQ33912263-E23C3D01-6D12-45D5-82E9-6D3F52B5DB22Q33912911-A1EC8014-CE95-4737-8471-AAB79DF049A2Q33990428-CA135B49-9430-411B-8F4C-79DEC1CD38B2Q34050936-9BC46F4A-CC1E-4DA8-BAC0-8FCB19A2D6B1Q34061511-225DACAD-6278-4C99-B834-935AF77A4E3EQ34065133-D0BB76C3-6108-47CE-84DF-F5804C35A2EEQ34147587-74BD4E57-5F56-489B-B4F9-D866E94BFB2EQ34179616-E377EBB3-51AC-4FE8-82F3-72873E796C0CQ34219746-0CC880EB-2203-40E9-87D5-E32238C1D537Q34252907-76035482-D578-4812-955E-4E10CAAF7684Q34284362-C1788688-8C15-4C56-AAE5-606593F32F59Q34362277-B3974D73-54F4-4A50-BC56-0A998314486DQ34415944-FC91E0FF-A3CA-4970-9461-EF0340755366Q34417386-88C96C42-41C4-43B4-A416-823F80EC42D8Q34418092-5CDE3650-C665-455C-A13F-A39CBD95FF62Q34530230-D5507F09-C6CE-4CFE-9889-5F588D2DD349Q34731671-F0A78B19-84BC-4AD9-AB12-205D3654A911Q34746151-1CE63978-79BF-405C-8A40-F26FA69A3501
P2860
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A polymorphism in the VKORC1 g ...... icoagulant effect of warfarin.
@en
A polymorphism in the VKORC1 g ...... icoagulant effect of warfarin.
@nl
type
label
A polymorphism in the VKORC1 g ...... icoagulant effect of warfarin.
@en
A polymorphism in the VKORC1 g ...... icoagulant effect of warfarin.
@nl
prefLabel
A polymorphism in the VKORC1 g ...... icoagulant effect of warfarin.
@en
A polymorphism in the VKORC1 g ...... icoagulant effect of warfarin.
@nl
P2093
P1433
P1476
A polymorphism in the VKORC1 g ...... ticoagulant effect of warfarin
@en
P2093
Giovanna D'Andrea
Massimiliano Chetta
Pasquale Di Perna
Rosa Lucia D'Ambrosio
Rosa Santacroce
Vincenzo Brancaccio
P304
P356
10.1182/BLOOD-2004-06-2111
P407
P577
2004-09-09T00:00:00Z